Hot topics in antibody-drug conjugate development

被引:0
|
作者
Thudium, Karen [1 ]
Bilic, Sanela [1 ]
机构
[1] Novartis Pharmaceut, Clin Pharmacol, Oncol Business Unit, E Hanover, NJ 07936 USA
关键词
BIOANALYTICAL METHOD VALIDATION; MACROMOLECULES;
D O I
10.4155/BIO.13.276
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
American Association of Pharmaceutical Scientists National Biotechnology Conference Sheraton San Diego Hotel and Marina, San Diego, CA, USA, 19-23 May 2013 The National Biotechnology Conference, is a premier meeting for biotechnology professionals covering a broad range of hot topics in the biotechnology industry. Attracting participants from academia, industry and regulatory, this meeting features sessions that aim to address emerging subjects of interest and allows for open exchange between scientists. The 2013 conference featured leading researchers in the fields of antibody-drug conjugates (ADCs) and immunogenicity. Herein, we present a summary of the ADC hot topics, including bioanalytical and PK considerations, quantitative evaluation of the impact of immunogenicity and ADME to understand ADC drug-drug interactions, and clinical considerations for ADC development. This article aims to summarize the recommendations that were made by the speakers during various sessions throughout the conference.
引用
收藏
页码:2989 / 2993
页数:5
相关论文
共 50 条
  • [41] Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics
    Sukumaran, Siddharth
    Zhang, Crystal
    Leipold, Douglas D.
    Saad, Ola M.
    Xu, Keyang
    Gadkar, Kapil
    Samineni, Divya
    Wang, Bei
    Milojic-Blair, Marija
    Carrasco-Triguero, Montserrat
    Rubinfeld, Bonnee
    Fielder, Paul
    Lin, Kedan
    Ramanujan, Saroja
    AAPS JOURNAL, 2017, 19 (01): : 130 - 140
  • [42] Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics
    Siddharth Sukumaran
    Crystal Zhang
    Douglas D. Leipold
    Ola M. Saad
    Keyang Xu
    Kapil Gadkar
    Divya Samineni
    Bei Wang
    Marija Milojic-Blair
    Montserrat Carrasco-Triguero
    Bonnee Rubinfeld
    Paul Fielder
    Kedan Lin
    Saroja Ramanujan
    The AAPS Journal, 2017, 19 : 130 - 140
  • [43] Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development
    Singh, Aman P.
    Shin, Young G.
    Shah, Dhaval K.
    PHARMACEUTICAL RESEARCH, 2015, 32 (11) : 3508 - 3525
  • [44] A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate
    Xiao, Dian
    Zhao, Lei
    Xie, Fei
    Fan, Shiyong
    Liu, Lianqi
    Li, Wei
    Cao, Ruiyuan
    Li, Song
    Zhong, Wu
    Zhou, Xinbo
    THERANOSTICS, 2021, 11 (06): : 2550 - 2563
  • [45] Antibody-drug conjugate and novel therapy in lung cancer
    Cho, B.
    ANNALS OF ONCOLOGY, 2024, 35 : S1310 - S1311
  • [46] Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate
    Sheyi, Rotimi
    de la Torre, Beatriz G.
    Albericio, Fernando
    PHARMACEUTICS, 2022, 14 (02)
  • [47] Macrocyclic pyrrolobenzodiazepine dimers as antibody-drug conjugate payloads
    Donnell, Andrew F.
    Zhang, Yong
    Stang, Erik M.
    Wei, Donna D.
    Tebben, Andrew J.
    Perez, Heidi L.
    Schroeder, Gretchen M.
    Pan, Chin
    Rao, Chetana
    Borzilleri, Robert M.
    Vite, Gregory D.
    Gangwar, Sanjeev
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (23) : 5267 - 5271
  • [48] Lung cancer treatment with antibody-drug conjugate (ADC)
    Hotta, Katsuyuki
    CANCER SCIENCE, 2018, 109 : 818 - 818
  • [49] Antibody-Drug Conjugate (ADC) Research in Ophthalmology—a Review
    Jie Shen
    Mayssa Attar
    Pharmaceutical Research, 2015, 32 : 3572 - 3576
  • [50] Antibody-Drug Conjugate Payloads; Study of Auristatin Derivatives
    Akaiwa, Michinori
    Dugal-Tessier, Julien
    Mendelsohn, Brian A.
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2020, 68 (03) : 201 - 211